51. Scleroderma Clinical trials / Disease details

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

  
5 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04303208
(ClinicalTrials.gov)		December 20203/3/2020Plasmacytoid Dendritic Cells and Toll Like Receptor 8 in Systemic SclerosisPlasmacytoid Dendritic Cells and Toll Like Receptor 8 in Systemic SclerosisSystemic SclerosisProcedure: 2 ml of whole blood sample will be collected on EDTA tubeAssiut UniversityNULLNot yet recruiting18 YearsN/AAll80N/ANULL
2NCT04265144
(ClinicalTrials.gov)		June 8, 20205/2/2020Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference CentreCohort of Patients With Systemic Sclerosis and Associated Biological Collection Within the Framework of the RESO Reference Centre for Rare Systemic Autoimmune DiseasesScleroderma;Systemic SclerosisBiological: Blood samples;Other: Biopsy;Other: Bronchoalveolar samplesUniversity Hospital, BordeauxNULLRecruiting18 YearsN/AAll500N/AFrance
3NCT03575156
(ClinicalTrials.gov)		September 20, 20187/6/2018Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic SclerosisMicroparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic SclerosisSystemic Lupus Erythematosus;Systemic SclerodermaBiological: blood sample;Biological: urine sampleUniversity Hospital, BordeauxNULLActive, not recruiting18 YearsN/AAll208N/AFrance
4NCT03508375
(ClinicalTrials.gov)		May 15, 201816/4/2018Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic SclerosisEvaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic SclerosisSystemic SclerodermaBiological: blood samplesAssistance Publique Hopitaux De MarseilleNULLRecruiting18 YearsN/AAll75N/AFrance
5NCT02562079
(ClinicalTrials.gov)		March 201229/12/2014Vasculopathy, Inflammation and Systemic SclerosisVasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte ActivationSystemic SclerosisBiological: Blood samples;Biological: BiopsyUniversity Hospital, BordeauxSociété Française de RhumatologieCompleted18 Years75 YearsAll350N/AFrance

Back to top